Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the t…
$399.63-0.12%
报价 2026-11-06
市值
$9.23B
EV
$10.43B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -33.7%
$396.32$602.83
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MDGLMadrigal Pharmaceuticals, Inc. | $9.23B | -0.1% | +57.5% | 94.1% | – | – | – | |
| MRNAModerna, Inc. | $101.48B | +5.3% | +9.3% | -12.6% | – | – | – | |
| EXELExelixis, Inc. | $17.49B | +1.3% | +11.8% | 96.4% | 14.4x | 11.5x | 20.6x | |
| JAZZJazz Pharmaceuticals plc | $15.07B | +3.3% | – | 88.2% | – | 109.6x | – | |
| BAXBaxter International Inc. | $13.34B | +0.5% | +5.8% | 33.4% | – | 25.2x | 13.3x | |
| TECHBio-Techne Corporation | $11.43B | +0.2% | +4.6% | 65% | 99.6x | 43.2x | 42.2x | |
| BMRNBioMarin Pharmaceutical Inc. | $10.85B | -0.2% | +21.6% | 77.1% | 30.1x | 17.2x | 14.9x | |
| RYTMRhythm Pharmaceuticals, Inc. | $7.73B | +6.9% | +57.7% | 88.2% | – | – | – | |
| ABVXAbivax S.A. | $7.5B | +1.8% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +10.5% | 71% | 30.1x | 25.2x | 17.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。